Archive
Nicholas Crisp’s NHI Departure Raises Leadership Concerns
Nicholas Crisp’s NHI departure comes as South Africa’s Health Department faces court challenges, senior suspensions and funding pressures.
Read More
GEMS Contribution Increase Sparks Union Backlash
The GEMS contribution increase remains at 9.5% after the CMS rejected a further reduction, prompting criticism from public sector unions.
Read More
Ebola Treatment Trials Need Urgent $18m Funding
Ebola treatment trials in the DRC need at least $18m in urgent funding to test experimental drugs and strengthen contact tracing.
Read More
Healthcare Access During Protests: SAMA Issues Warning
Healthcare access during protests must be protected, SAMA says, as anti-immigration marches raise safety concerns.
Read More
Unsafe Cosmetic Procedures Raise SA Health Alarm
Unsafe cosmetic procedures using unregulated injectables have prompted a national health warning after two patients suffered kidney failure.
Read More
Hospital CEO Vacancies Raise Governance Concerns
Hospital CEO vacancies are raising concerns about governance, accountability and service delivery across the public health system.
Read More
Shingrix launch in South Africa Raises Access Concerns
Shingrix is set to launch in South Africa, promising better shingles protection. Find out what this means for patients and costs.
Read More
Lenacapavir HIV Prevention Could Transform South Africa
Lenacapavir HIV prevention offers twice-yearly PrEP, but trust, access, stigma and continued engagement will determine its impact.
Read More
Global HIV Treatment Gap Leaves 8.8 Million Behind
Global HIV treatment gap leaves 8.8 million people without therapy as funding cuts weaken testing, prevention and community-led services.
Read More
AI Alternatives To Animal Testing Gain Momentum
AI alternatives to animal testing can predict toxicity and organ damage while offering more ethical and human-relevant research methods.
Read More
US Prescription Drug Spending to Top $560bn in 2026
US prescription drug spending is forecast to exceed $560bn in 2026 as demand for GLP-1 obesity and diabetes treatments continues to rise.
Read More
iDexis Semaglutide Ban Ordered By High Court
iDexis semaglutide ban stops the pharmacy group from selling compounded weight-loss medicines while SAHPRA and the SAPC investigate.
Read More